Literature DB >> 22499018

Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study.

Xavier Castellsagué1, Thomas Iftner, Esther Roura, José Antonio Vidart, Susanne K Kjaer, F Xavier Bosch, Nubia Muñoz, Santiago Palacios, Maria San Martin Rodriguez, Laurence Serradell, Laurence Torcel-Pagnon, Javier Cortes.   

Abstract

Human papillomavirus (HPV) infection is a necessary cause of cervical cancer. The aim of this study was to estimate the prevalence of cervical HPV infection and HPV type-specific distribution among women attending cervical cancer screening in Spain during 2007 and 2008. Women aged 18-65 years were recruited according to an age-stratified sampling method. Liquid-based cervical samples were collected and analyzed for cytology, HPV detection, and genotyping. HPV genotyping was determined using the INNO-LiPA HPV Genotyping Extra Reverse Hybridization Line Probe Assay. Prevalence estimates were age-standardized using 2001 Spanish census data. The present study included 3,261 women. Age-standardized HC2-based HPV prevalence was 14.3% (95% CI, 13.1-15.5) among women aged 18-65 years, and 28.8% (26.6-31.1) among women aged 18-25 years. High-risk HPV types were detected in 12.2% (95% CI, 11.1-13.4) of HPV-tested women, representing 84.0% of HPV-positive samples. Multiple infections were present in 4.1% (95% CI, 3.4-4.8) of HPV-tested women (25.0% of HPV-positive samples). The most common high-risk HPV-types among HPV-tested women were 16 (2.9%), 52 (1.8%), 51 (1.6%), 31 (1.3%), and 66 (1.2%). HPV-type 16 was present in 16.9% of HPV-positive samples. One or more of the HPV vaccine types 6/11/16/18 were detected in 3.8% of HPV-tested women (22.1% of HPV-positive samples). Though not a true population-based survey, this study provides valuable baseline data for future assessment of the impact of current HPV vaccination programs in Spain. The high prevalence of HPV infection among young women may reflect recent changes in sexual behavior.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22499018     DOI: 10.1002/jmv.23282

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  30 in total

1.  RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval.

Authors:  Elisa Martín-Merino; Ana Llorente-García; Dolores Montero Corominas; Consuelo Huerta-Álvarez
Journal:  Pharmaceut Med       Date:  2019-04

2.  The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.

Authors:  Elisa Martín-Merino; Ana Llorente-García; Belén Castillo Cano; Dolores Montero Corominas; Consuelo Huerta-Álvarez
Journal:  Pharmaceut Med       Date:  2019-12

3.  Prevalence of human papillomavirus infection in Argentinean women attending two different hospitals prior to the implementation of the National Vaccination Program.

Authors:  Diego Chouhy; Rubén Mamprín D'Andrea; Mercedes Iglesias; Analía Messina; Juan J Ivancovich; Belen Cerda; Diana Galimberti; Hebe Bottai; Adriana A Giri
Journal:  J Med Virol       Date:  2013-01-07       Impact factor: 2.327

4.  Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014-2015.

Authors:  Monserrat Balanda; Andrea Quiero; Nicolás Vergara; Gloria Espinoza; Héctor San Martín; Giovanna Rojas; Eugenio Ramírez
Journal:  Med Microbiol Immunol       Date:  2016-08-18       Impact factor: 3.402

5.  Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study.

Authors:  Esther Roura; Thomas Iftner; José Antonio Vidart; Susanne Krüger Kjaer; F Xavier Bosch; Nubia Muñoz; Santiago Palacios; Maria San Martin Rodriguez; Carmen Morillo; Laurence Serradell; Laurence Torcel-Pagnon; Javier Cortes; Xavier Castellsagué
Journal:  BMC Infect Dis       Date:  2012-06-26       Impact factor: 3.090

6.  Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany.

Authors:  Karl Ulrich Petry; Alexander Luyten; Annika Justus; Angelika Iftner; Sarah Strehlke; Renate Schulze-Rath; Thomas Iftner
Journal:  BMC Infect Dis       Date:  2012-12-21       Impact factor: 3.090

7.  Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancer.

Authors:  Valeria Stuardo; Cristina Agustí; José Manuel Godinez; Alexandra Montoliu; Aureli Torné; Antoni Tarrats; Carmen Alcalde; Dolores Martín; Eulalia Fernández-Montoli; Cristina Vanrell; Josefa Solé; Yolanda Canet; José Manuel Marqueta; Jadiyettu Mohamed; Isabel Cuenca; Montserrat Lonca; Guillem Sirera; Elena Ferrer; Pere Domingo; Belen Lloveras; Josep María Miro; Silvia De Sanjosé; Jordi Casabona
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

8.  Cross-sectional study about primary health care professionals views on the inclusion of the vaccine against human papillomavirus in the vaccine schedules.

Authors:  M Reyes Oliver Pérez; Victoria Bravo Violeta; Ana Vazquez Del Campo; Cristina Ruiz; Sonia Yáñez Castaño; Laura P Pérez Conde; Jesús S Jiménez López
Journal:  Infect Agent Cancer       Date:  2015-11-16       Impact factor: 2.965

Review 9.  HPV Infection in Cervical and Other Cancers in Saudi Arabia: Implication for Prevention and Vaccination.

Authors:  Ghazi Alsbeih
Journal:  Front Oncol       Date:  2014-03-31       Impact factor: 6.244

10.  Ethical considerations of universal vaccination against human papilloma virus.

Authors:  Pedro Navarro-Illana; Justo Aznar; Javier Díez-Domingo
Journal:  BMC Med Ethics       Date:  2014-04-07       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.